Statins have an early antiplatelet effect in patients with acute myocardial infarction

Platelets

Volumn 22, Issue 2, 2011, Pages 103-110

  Matetzky, Shlomi ^a   Fefer, Paul ^a   Shenkman, Boris ^b   Shechter, Michael ^a   Novikov, Ilia ^c   Savion, Naphtali ^d   Varon, David ^e   Hod, Hanoch ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b Institute of Hematology   (Israel)

^c GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

antiplatelet drugs; Myocardial infarction; platelet deposition; statins; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; ATORVASTATIN; CLOPIDOGREL; COLLAGEN; EPTIFIBATIDE; MEVINOLIN; N(G) METHYLARGININE; PRAVASTATIN; SIMVASTATIN;

ACUTE HEART INFARCTION; ADULT; AGED; AGGREGOMETRY; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HOSPITAL ADMISSION; HUMAN; HYDROPHILICITY; IN VITRO STUDY; LIPOPHILICITY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE MEMBRANE;

ADENOSINE DIPHOSPHATE; AGED; ANGIOPLASTY, BALLOON, CORONARY; ARACHIDONIC ACID; BLOOD PLATELETS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PRAVASTATIN; SIMVASTATIN;

EID: 79751481982     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2010.512402     Document Type: Article

References (27)

1. Osamah H, Mira R, Sorina S, Shlomo K, Michael A. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Brit J Clin Pharmacol 1997;44:77-83.
2. Dangas G, Badimon JJ, Smith DA, Unger AH, Levine D, Shao JH, Meraj P, Fier C, Fallon JT, Ambrose JA. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the system hemostatic profile. J Am Coll Cardiol 1999;33: 1294-1304.
3. Sanguigni V, Pignatelli P, Lenti L, Ferro D, Bellia A, Carnevale R, Tesauro M, Sorge R, Lauro R, Violi F. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 2005;111:412-419. (Pubitemid 40204424)
4. Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB. Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995;92:3172-3177.
5. Rauch U, Osende JI, Chesebro JH, Fuster V, Vorchheimer DA, Harris K, Harris P, Sandler DA, Fallon JT, Jayaraman S, Badimon JJ. Statins and cardiovascular diseases: The multiple effects of lipid-lowering therapy by statins. Atherosclerosis 2000;153:181-189.
6. Thompson PD, Moyna NM, White CM, Weber KM, Giri S, Waters DD. The effects of hydroxy-methyl-glutaryl co-enzyme A reductase inhibitors on platelet thrombus formation. Atherosclerosis 2002;161:301-306. (Pubitemid 34219182)
7. Alfon J, Royo T, Garcia-Moll X, Badimon L. Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin. Arterioscler Thromb Vasc Biol 1999;19:1812-1817. (Pubitemid 29323844)
8. Laufs U, Gertz K, Huang P, Weber KM, Giri S, Waters DD. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000;31:2442-2449.
9. Tailor A, Lefer DJ, Granger DN. HMG-CoA reductase inhibitor attenuates platelet adhesion in intestinal venules of hypercholesterolemic mice. Am J Physiol - Heart & Circ Physiol 2004;286:H1402-H1407. (Pubitemid 38381148)
10. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metabolism & Disposition 2003;31:53-9. (Pubitemid 36735258)
11. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DC, Guyer KE, Bates ER. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction. Circulation 2003;107:32-37. (Pubitemid 36070929)
12. Neubauer H, Gunesdogan B, Hanefeld C, Spiecker M, Mugge A. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function - a flow cytometry study. Eur Heart J 2003;24:1744-1749. (Pubitemid 37236863)
13. Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, Topol EJ. Clopidogrel for the reduction of events during observation investigators. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003;108:921-924. (Pubitemid 37048218)
14. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004;109:1335-1338. (Pubitemid 38387816)
15. Gorchakova O, von Beckerath N, Gawaz M, Mocz A, Joost A, Schomig A, Kastrati A. Antiplatelet effects of a 600mg loading dose of clopidogrel are not attenuated n patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 2004;25:1898-1902. (Pubitemid 39452606)
16. Lim MJ, Spencer FA, Gore JM, Dabbous OH, Agnelli G, Kline-Rogers EM, Dibenedetto D, Eagle KA, Mehta RH. GRACE Investigators. Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: Perspectives from a large multinational registry. Eur Heart J 2005;26:1063-1069. (Pubitemid 40839906)
17. Varon D, Dardik R, Shenkman B, Kotev-Emeth S, Farzame N, Tamarin I, Savion N. A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions. Thromb Res 1997;85:283-294. (Pubitemid 27143804)
18. Puccetti L, Pasqui AL, Pastorelli M, Bova G, Cercignani M, Palazzuoli A, Angori P, Auteri A, Bruni F. Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest 2002;32:901-908. (Pubitemid 35478062)
19. Gaddam V, Li DY, Mehta JL. Anti-thrombotic effects of atorvastatin - an effect unrelated to lipid lowering. J Cardiovasc Pharmacol Ther 2002;7:247-253. (Pubitemid 35471361)
20. Santos MT, Fuset MP, Ruano M, Moscardo A, Valles J. Effect of atorvastatin on platelet thromboxane A2 synthesis in aspirintreated patients with acute myocardial infarction. Am J Cardiol 2009;104:1618-1623.
21. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E. Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98:839-844. (Pubitemid 28397432)
22. Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Madsen TE, Hart NI, Anderson JI. Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease. Circulation 2003;107:258-263. (Pubitemid 36135221)
23. Price MJ, Navak KR, Barker CM, Kandzari DE, Teirstein PS. Predictors of heightened platelet reactivity despite dualantiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009;10:1339-1343.
24. Desai NR, Mega JL, Jiano S, Cannon CP, Sabatine MS. Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 2009;53:1273-1278.
25. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Pravastatin or atorvastatin evaluation and infection therapythrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504.
26. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: Results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study. Circulation 2004;110:674-678. (Pubitemid 39056265)
27. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B. Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;287:3215-3222. (Pubitemid 34686102)